NEW YORK, NY / ACCESSWIRE / December 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Merit Medical Systems, Inc. (NASDAQ:MMSI)
Class Period: February 26, 2019 to October 30, 2019
Lead Plaintiff Deadline: February 3, 2020

The MMSI lawsuit alleges that Merit Medical Systems, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the integrations of acquired companies Cianna Medical, Inc. and Vascular Insights, LLC, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during FY19; and (c) in light of the foregoing, the Company's reported financial guidance for FY19 and FY20 was made without a reasonable basis.

Learn about your recoverable losses in MMSI: http://www.kleinstocklaw.com/pslra-1/merit-medical-systems-inc-loss-submission-form?id=4842&from=1

Armstrong Flooring, Inc. (NYSE:AFI)
Class Period: March 6, 2018 to November 4, 2019
Lead Plaintiff Deadline: January 14, 2020

The complaint alleges that throughout the class period Armstrong Flooring, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had engaged in channel stuffing to artificially boost sales; (2) the Company's internal control over inventory levels was not effective; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis

Learn about your recoverable losses in AFI: http://www.kleinstocklaw.com/pslra-1/armstrong-flooring-inc-loss-submission-form?id=4842&from=1

Fiat Chrysler Automobiles N.V. (NYSE:FCAU)
Class Period: February 26, 2016 to November 20, 2019
Lead Plaintiff Deadline: January 31, 2020

Fiat Chrysler Automobiles N.V. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company employed a bribery scheme to obtain favorable terms in its collective bargaining agreement with United Automobile, Aerospace and Agricultural Implement Workers of America; (2) high-ranking Fiat officials were aware of and authorized the scheme; and (3) as a result, Defendants' statements about Fiat's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in FCAU: http://www.kleinstocklaw.com/pslra-1/fiat-chrysler-automobiles-n-v-loss-submission-form?id=4842&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 569949

NEW YORK, NY / ACCESSWIRE / December 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Sealed Air Corporation (NYSE:SEE)
Class Period: November 5, 2014 to August 6, 2018
Lead Plaintiff Deadline: December 31, 2019

The SEE lawsuit alleges Sealed Air Corporation made materially false and/or misleading statements and/or failed to disclose during the class period that: (a) Sealed Air had hired its auditor, E&Y, pursuant to a conflicted and improper process and in order to help facilitate defendants' efforts to engage in accounting fraud; (b) Sealed Air's deduction of $1.49 billion in connection with the Settlement was indefensible and done for the improper purpose of artificially inflating the Company's financial results; (c) Sealed Air had artificially inflated its earnings, cash flows, and operating income during the Class Period; (d) as a result of the above, Sealed Air's Class Period financial statements were materially false and misleading and not prepared in conformance with GAAP; and (e) as a result of the above, Sealed Air's statements regarding its financial results, business, and prospects were materially misleading.

Learn about your recoverable losses in SEE: http://www.kleinstocklaw.com/pslra-1/sealed-air-corporation-loss-submission-form?id=4841&from=1

Wanda Sports Group Company Limited (NASDAQ:WSG)
Class Period: Wanda Sports' securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Wanda Sports' July 26, 2019 initial public offering.
Lead Plaintiff Deadline: January 17, 2020

Wanda Sports Group Company Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the lack of major sporting events for its Digital, Production, Sports Solutions ("DPSS") and Spectator Sports segments for its second quarter of 2019, ending before the initial public offering, would negatively impact revenue for the second quarter of 2019; (2) Wanda Sports had suffered a year-over-year decrease in revenue in its second quarter ended June 30, 2019 and would for its fiscal year 2019, primarily related to lower reimbursement revenues accounted for in its DPSS segment and lack of Spectator Sport segment offsets; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in WSG: http://www.kleinstocklaw.com/pslra-1/wanda-sports-group-company-limited-loss-submission-form?id=4841&from=1

iRobot Corporation (NASDAQ:IRBT)
Class Period: November 21, 2016 to October 22, 2019
Lead Plaintiff Deadline: December 23, 2019

The filed complaint alleges that defendants misrepresented the reason for iRobot's acquisitions of Tokyo-based Sales on Demand Corporation and privately-held Robopolis SAS, which was to control the Company's largest distributors so that defendants could inflate sales and revenue figures by stuffing the channel. Defendants further misled investors by repeatedly telling them throughout the Class Period that the Company was seeing continued double-digit revenue growth, and by attributing the growth to increased demand for the Roomba vacuums, when in reality defendants were engaging in channel-stuffing to artificially boost sales. Defendants also misstated that the Company's channel inventory levels had not changed and would not change dramatically from quarter to quarter or year over year, when in fact iRobot was deliberately stuffing the channel in order to claim false revenue growth.

Learn about your recoverable losses in IRBT: http://www.kleinstocklaw.com/pslra-1/irobot-corporation-loss-submission-form?id=4841&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 569945

ANN ARBOR, MI / ACCESSWIRE / December 11, 2019 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), today announced that it has closed an $8.1 million private placement of its Series A Convertible Preferred Stock ("Preferred Stock"), common stock and warrants to purchase common stock ("Warrants"). ENDRA intends to use the net proceeds for working capital and general corporate purposes, including to support its commercialization initiatives and ongoing clinical studies.

The company used approximately $1.9 million of net proceeds from the offering to repay debt represented by convertible promissory notes issued in July 2019. Remaining net proceeds from the offering were approximately $5.4 million, after deducting estimated fees and expenses.

The company issued Warrants exercisable for approximately 8.2 million shares of common stock. Assuming an effective registration statement on file, the Warrants are exercisable only for cash and have a forced exercise feature in the event that the daily volume weighted-average closing price of the company's common stock averages over $1.74 for a 10-trading day period. This represents potential additional proceeds of approximately $7.1 million.

Several members of ENDRA's senior management team and board of directors, alongside existing investors of ENDRA, participated in the offering. Lake Street Capital Markets acted as ENDRA's exclusive placement agent for the offering.

"This was a transformative financing for the company as we believe that we are now capitalized through the anticipated regulatory approvals and initial commercialization of the TAEUS liver device. We would like to thank our investors for their continued support and belief in the promise of our TAEUS technology," said Francois Michelon, ENDRA's Chief Executive Officer.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements.

Further details regarding this private placement, including further description of the terms of the Preferred Stock and Warrants, can be found in ENDRA's Form 8-K filed with the Securities and Exchange Commission on December 11, 2019.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology being developed to visualize tissue like CT or MRI, but at 1/50th of the cost, at the point of patient care. TAEUS is designed to work in concert with the over one million ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.www.endrainc.com

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, statements we make regarding expectations concerning the anticipated use of proceeds from the private placement; the amount of proceeds that may be received upon the exercise of any Warrants; estimates of the timing of future events and achievements, including obtaining a CE Mark and U.S. Food and Drug Administration ("FDA") 510(k) approval and commercializing the TAEUS device; and expectations concerning ENDRA's product development and business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, the following: no Warrants ever being exercised for cash, resulting no further proceeds to ENDRA; our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:

MacDougall
Christi Waarich
(781) 235-3060
endra@macbiocom.com

SOURCE: ENDRA Life Sciences Inc.

ReleaseID: 569899

NEW YORK, NY / ACCESSWIRE / December 11, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Uniti Group Inc. (NASDAQGS:UNIT)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/uniti-group-inc-loss-submission-form?prid=4840&wire=1
Lead Plaintiff Deadline: December 30, 2019
Class Period: April 20, 2015 to February 15, 2019

Allegations against UNIT include that: (i) Uniti's financial results were not sustainable because its customer Windstream had defaulted on its unsecured notes; and (ii) as a result of the foregoing, Defendants' statements about Uniti's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Under Armour, Inc. (NYSE:UA)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/under-armour-inc-loss-submission-form?prid=4840&wire=1
Lead Plaintiff Deadline: January 6, 2020
Class Period: August 3, 2016 to November 1, 2019

Allegations against UA include that: (1) Under Armour shifted sales from quarter to quarter to appear healthier, including to keep pace with their long-running year-over-year 20% net revenue growth; (2) undisclosed to the investing public, the Company had been under investigation by and cooperating with the U.S. Department of Justice and U.S. Securities and Exchange Commission since at least July 2017; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

UP Fintech Holding Limited (NASDAQ:TIGR)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/up-fintech-holding-limited-loss-submission-form?prid=4840&wire=1
Lead Plaintiff Deadline: January 6, 2020
Class Period: all persons and entities that purchased or otherwise acquired: (a) Fintech American Depository Shares pursuant and/or traceable to the Company's initial public offering conducted on or about March 20, 2019; or (b) Fintech securities between March 20, 2019 and May 16, 2019.

Allegations against TIGR include that: (i) Fintech was experiencing a material decrease in commissions because of a negative trend related to risk-averse investors in the market; (ii) Fintech was unable to absorb costs associated with the rapid growth of its business and its status as a publicly listed company on a U.S. exchange; (iii) Fintech was incurring significant additional expenses related to, inter alia, employee headcount and employee compensation and benefits; (iv) all of the foregoing had led to Fintech significantly increasing operating costs and expenses; and (v) as a result, the documents filed by the Company in connection with the initial public offering were materially false and/or misleading and failed to state information required to be stated therein, and the Company's Class Period statements were likewise materially false and/or misleading.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 569943

NEW YORK, NY / ACCESSWIRE / December 11, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Pareteum Corporation (NASDAQ:TEUM)

TEUM Lawsuit on behalf of: investors who purchased December 14, 2017 – October 21, 2019
Lead Plaintiff Deadline: December 23, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/pareteum-corporation-loss-form?prid=4839&wire=1

According to the filed complaint, during the class period, Pareteum Corporation made materially false and/or misleading statements and/or failed to disclose that: (a) it was not true that the Company's purported success was the result of hyper-demand for Pareteum's unique products or exceptional service, or the Company's competent management; but, in fact, Defendants had propped up the Company's results by manipulating Pareteum's accounting for revenues, income, and the important Backlog metric; (b) Defendants had materially overstated the Company's profitability by failing to properly account for the Company's results of operations and by artificially inflating the Company's financial results; (c) it was not true that Pareteum contained even the most minimally adequate systems of internal operational or financial controls necessary to assure that Pareteum's reported financial statements were true, accurate, and/or reliable; (d) as a result, it also was not true that the Company's financial statements and reports were prepared in accordance with GAAP and SEC rules; and (e) as a result of the aforementioned adverse conditions, Defendants lacked any reasonable basis to claim that Pareteum was operating according to plan, or that Pareteum could achieve the guidance sponsored and/or endorsed by Defendants.

Quad/Graphics, Inc. (NYSE:QUAD)

QUAD Lawsuit on behalf of: investors who purchased February 21, 2018 – October 29, 2019
Lead Plaintiff Deadline: January 6, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/quad-graphics-inc-loss-form?prid=4839&wire=1

According to the filed complaint, during the class period, Quad/Graphics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's book business in United States was underperforming; (2) as a result, the Company was likely to divest its book business; (3) the Company was unreasonably vulnerable to decreases in market prices; (4) to remain financially flexible while market prices decreased, the Company was likely to cut its quarterly dividend and expand its cost reduction programs; and (5) as a result of the foregoing, positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Yunji Inc. (NASDAQ:YJ)

YJ Lawsuit on behalf of: investors who purchased on behalf of shareholders who purchased or otherwise acquired Yunji American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2019 initial public offering.
Lead Plaintiff Deadline: January 13, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/yunji-inc-loss-form?prid=4839&wire=1

According to the filed complaint, (1) the Company was shifting certain of its sales to its marketplace platform; (2) this supply chain restructuring was likely to disrupt Yunji's relationships with suppliers; (3) this supply chain restructuring was likely to have an adverse impact on the Company's financial results; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 569942

NEW YORK, NY / ACCESSWIRE / December 11, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)
ADMS Lawsuit on behalf of: investors who purchased August 8, 2017 – September 30, 2019
Lead Plaintiff Deadline: February 10, 2020
Join the action: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?wire=3&prid=4837

About the ADMS lawsuit: During the class period, Adamas Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

To learn more about the Adamas Pharmaceuticals, Inc. class action, contact jlevi@levikorsinsky.com.

X Financial (NYSE:XYF)
XYF Lawsuit on behalf of: investors who purchased X Financial American Depositary Shares pursuant and/or traceable to the Company's September 19, 2018 initial public offering.
Lead Plaintiff Deadline: February 7, 2020
Join the action: https://www.zlk.com/pslra-1/x-financial-loss-form?wire=3&prid=4837

About the XYF lawsuit: Throughout the class period, X Financial allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's total loan facilitation amount was not growing, but rather was contracting; (ii) the number of investors actively using X Financial's platform was shrinking; (iii) demand from small- and medium-sized enterprises for the Company's preferred loans was plummeting; (iv) the Company's preferred loans had performed so poorly that it had begun drastically scaling back its preferred loans in the first quarter of 2018, several months before the initial public offering ("IPO"), and was in the process of phasing out such loans completely; (v) demand for the Company's card loans was also plummeting; (vi) the revenue and loan facilitation growth provided in the registration statement leading up to the IPO was achieved by relaxed credit and due diligence standards, under which the Company had underwritten tens of millions of dollars' worth of poor quality loans that suffered from a disproportionately high risk of default as compared to the Company's earlier loan vintages; (vii) the Company was suffering from accelerated delinquency rates from poor quality loans that it had underwritten in the first, second, and third quarters of 2018, which had caused the Company's delinquency rate to sharply rise; (viii) the Company's product mix had significantly deteriorated; (ix) the Company's net revenue was on track to decline by 22% during the third quarter of 2018; and (x) as a result, the Registration Statement was materially false and/or misleading and failed to state information required to be stated therein.

To learn more about the X Financial class action, contact jlevi@levikorsinsky.com.

Baozun Inc. (NASDAQ:BZUN)
BZUN Lawsuit on behalf of: investors who purchased Baozun American Depository Receipts between March 6, 2019 and November 20, 2019
Lead Plaintiff Deadline: February 10, 2020
Join the action: https://www.zlk.com/pslra-1/baozun-inc-loss-form?wire=3&prid=4837

About the BZUN lawsuit: Baozun Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (a) Baozun was heavily reliant upon a single brand partner, Huawei, for the exponential service fee growth it had been reporting historically, which was in turn fueling its historical revenue growth; (b) compared to other brands Baozun had as brand partners, the Huawei work had historically included a lot of additional add-on service fees, increasing the revenue reported from Huawei vis-a-via its other brand partners; (c) Huawei, like other large brands, was actively preparing to bring its online merchandising in-house, meaning Baozun knew that it was losing a significant brand partner; and (d) as a result of the foregoing, the Company was not on track to achieve the financial results and performance Defendants claimed the Company was on track to achieve during the class period.

To learn more about the Baozun Inc. class action, contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 569941

LOS ANGELES, CA / ACCESSWIRE / December 11, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AZZ Inc. ("AZZ" or "the Company") (NYSE:AZZ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between July 3, 2018 and October 8, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 3, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. AZZ failed to maintain appropriate and effective controls on financial reporting. The Company's improper implementation of ASC 606 resulted in incorrect revenue reconciliations. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about AZZ, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 569929

NEW YORK, NY / ACCESSWIRE / December 11, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Adamas Pharmaceuticals, Inc. (NASDAQGM:DMS)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/adamas-pharmaceuticals-inc-loss-submission-form?prid=4836&wire=1
Lead Plaintiff Deadline: February 10, 2020
Class Period: August 8, 2017 to September 30, 2019

Allegations against ADMS include that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Zendesk, Inc. (NYSE:ZEN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/zendesk-inc-loss-submission-form?prid=4836&wire=1
Lead Plaintiff Deadline: December 23, 2019
Class Period: February 6, 2019 to October 1, 2019

Allegations against ZEN include that: (a) Zendesk's clients had been subject to data breaches dating back to 2016; (b) Zendesk was experiencing slowing demand for its Software as a Service offerings, particularly in Germany, the United Kingdom, and Australia, due in large part to political uncertainty and China trade issues there; and (c) as a result of the foregoing, Zendesk's business metrics and financial prospects were not as strong as defendants had led the market to believe during the Class Period.

Grubhub Inc. (NYSE:GRUB)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/grubhub-inc-loss-submission-form?prid=4836&wire=1
Lead Plaintiff Deadline: January 20, 2020
Class Period: July 30, 2019 to October 28, 2019

Allegations against GRUB include that: (i) customer orders were actually declining, despite the massive investments that the Company had made to spur demand for and use of its platform; (ii) Grubhub's new customer additions were generating significantly lower revenues as compared to historic cohorts because these customers were more prone to using competitor platforms; (iii) Grubhub's vaunted business model under which it secured exclusive partnerships had failed, and Grubhub needed to engage in the same aggressive nonpartnered sales tactics embraced by its competitors to generate significant revenue growth; (iv) Grubhub was required to spend substantial additional capital in order to grow revenues and retain market share in the face of heightened competitive dynamics and market saturation, eviscerating the Company's profitability; and (v) Grubhub was tracking tens of millions of dollars below its revenue and earnings guidance and such guidance lacked any reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 569939

NEW YORK, NY / ACCESSWIRE / December 11, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

ADTRAN, Inc. (NASDAQ:ADTN)

ADTN Lawsuit on behalf of: investors who purchased February 28, 2019 – October 9, 2019
Lead Plaintiff Deadline : December 16, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/adtran-inc-loss-form?prid=4835&wire=1

According to the filed complaint, during the class period, ADTRAN, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there were material weaknesses in the Company's internal control over financial reporting; (2) as a result, certain E&O reserves had been improperly reported; (3) as a result, the Company's financial results for certain periods were misstated; (4) there would be a pause in shipments to the Company's Latin American customer; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Twitter, Inc. (NYSE:TWTR)

TWTR Lawsuit on behalf of: investors who purchased August 6, 2019 – October 23, 2019
Lead Plaintiff Deadline : December 30, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/twitter-inc-loss-form?prid=4835&wire=1

The filed complaint alleges that defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Twitter's common share price and operated as a fraud or deceit on purchasers of Twitter common stock by misrepresenting the Company's operating condition and future business prospects. The scheme was perpetrated by making positive statements about Twitter's business while defendants knew, or disregarded with deliberate recklessness, certain adverse facts. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Twitter's common stock fell precipitously.

Energy Transfer LP (NYSE:ET)

ET Lawsuit on behalf of: investors who purchased February 25, 2017 – November 11, 2019
Lead Plaintiff Deadline : January 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/energy-transfer-lp-loss-form?prid=4835&wire=1

According to the filed complaint, during the class period, Energy Transfer LP made materially false and/or misleading statements and/or failed to disclose that: (i) Energy Transfer's permits to conduct the Mariner East pipeline project in Pennsylvania were secured via bribery and/or other improper conduct; (ii) the foregoing misconduct increased the risk that the Partnership and/or certain of its employees would be subject to government and/or regulatory action, thereby depreciating the Partnership's unit value; and (iii) as a result, the Partnership's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 569937

VANCOUVER, BC / ACCESSWIRE / December 11, 2019 / Mr. Ryan Kalt announces that he has today acquired, directly, an aggregate of 2,110,000 units (each a "Unit") of Golden Lake Exploration Inc. (CSE: GLM) ("Golden Lake" or the "Company") by way of a private placement that closed on December 11, 2019.

Mr. Kalt paid an aggregate of $211,000.00 for the Units, representing an average purchase price of $0.10 per Unit.

Each Unit is comprised of one common share (a "Common Share") in the capital of Golden Lake and one transferable common share purchase warrant (a "Warrant"), with each Warrant entitling Mr. Kalt to purchase one Common Share for a 24-month period from the closing date at an exercise price of 15 cents per Common Share (the Common Shares and Warrants, together, the "Securities")

Mr. Kalt now owns 2,110,000 Common Shares of Golden Lake representing 10.90% of the issued and outstanding common shares of Golden Lake, and 2,110,000 Warrants of Golden Lake which, if exercised in full, would result in Mr. Kalt owning a combined post-exercise total of 4,220,000 Common Shares, being 19.66% of the issued and outstanding common shares of Golden Lake.

Mr. Kalt acquired the securities for investment purposes.

Mr. Kalt may acquire additional securities of Golden Lake either on the open market or through private acquisitions or sell securities of Golden Lake either on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors. Other than the foregoing, Mr. Kalt does not have plans or any future intentions which relate to or would result in any of the other foregoing matters.

"Ryan Kalt"
Ryan Kalt

The Form 62-103F1 – Required Disclosure under the Early Warning Requirements associated with this news release can be obtained from Golden Lake's profile on SEDAR at www.sedar.com. To obtain a copy of the report, please contact Mr. Kalt at 1.604.652.1710.

The CSE has not reviewed, approved or disapproved the contents of this press release.

SOURCE: Golden Lake Exploration Inc.

ReleaseID: 569936